SecBot SecBot
SECBOTREPLAY Home › Report › HRTX

HRTX · Q3 revenue -7.8% YoY, asset sale

HERON THERAPEUTICS, INC. /DE/ · 8-K filed Nov 9, 2026 at 08:15 ET

At the news

NEUTRALIMPACT 6/10

8-K filed Nov 9, 2026 at 08:15 ET

Heron Therapeutics reported Q3 2026 net revenue of $35.3M, down 7.8% YoY from $38.2M, with the Oncology franchise declining 22.2% (CINVANTI -16.6%, SUSTOL sales ceased). The company announced a definitive asset purchase agreement under which CorMedix Therapeutics will acquire substantially all of Heron's assets, subject to stockholder approval.

  • Q3 2026 net revenue of $35.3M, down 7.8% from $38.2M in Q3 2025
  • Acute Care franchise revenue up 22.5% YoY to $15.1M
  • Oncology franchise revenue down 22.2% YoY to $20.1M
  • CINVANTI revenue down 16.6% YoY to $20.0M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access